Allergan has been a pillar of the ophthalmology sector for decades, so it’s merger with Pfizer is creating some concern along with great optimism. But ophthalmology leaders also see the opportunity for potential in the combination. The deal could bring greater firepower to ophthalmology R&D and M&A and some hope it’s a harbinger of more things to come for the sector.